Skip to content

Insider · CIK 0001760104

Alfonso Quintas Cardama

officer

Files at FHTX (Foghorn Therapeutics Inc.). First filing -, latest -.

In brief

Alfonso Quintas Cardama files SEC Form 4 as officer at FHTX (Foghorn Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.

A track record needs three past buys with six months of prices behind them; Alfonso Quintas Cardama has 0, so none is measured yet.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold

Signals

This insider’s open-market buys and sells, scored.

No scored open-market trades yet.

Transactions

Every row this insider has filed, 2 in all, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Jan 30, 2026FHTX
Foghorn Therapeutics Inc.
AGrant or award
Stock option (right to buy)derivative
+300,000$5.71$1.7M300,000Feb 2, 2026
Jan 22, 2025FHTX
Foghorn Therapeutics Inc.
AGrant or award
Stock Option (right to buy)derivative
+125,000$4.37$546k125,000Jan 24, 2025

Questions about Alfonso Quintas Cardama

Answered from the filings on this page, as of the latest one.

Is Alfonso Quintas Cardama buying or selling?

Alfonso Quintas Cardama has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.

How did Alfonso Quintas Cardama's past buys perform?

Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Alfonso Quintas Cardama has 0.

Where does Alfonso Quintas Cardama file Form 4?

Alfonso Quintas Cardama has filed Form 4 at FHTX (Foghorn Therapeutics Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Alfonso Quintas Cardama: insider trades and track record | InsiderTell